Graphite Stock News

Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prim

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a D

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in

Graphite Bios (NASDAQ:GRPH) lock-up period is set to expire on Wednesday, December 22nd. Graphite Bio had issued 14,000,000 shares in its initial public offering on June 25th. The total size of the offering was $238,000,000 based on an initial share price of $17.00. After the expiration of the companys lock-up period, restrictions preventing major shareholders []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today presented a trial-in-progress poster for the companys Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). The poster is being presented at the 63rd American As

Graphite Bio, Inc. (NASDAQ:GRPH) shares traded up 3% during mid-day trading on Friday . The stock traded as high as $9.17 and last traded at $9.14. 1,665 shares were traded during trading, a decline of 100% from the average session volume of 334,214 shares. The stock had previously closed at $8.87. Several equities analysts recently []

Graphite Bio, Inc. (NASDAQ:GRPH) major shareholder Biocapital L.P. Samsara purchased 201,685 shares of the firms stock in a transaction on Monday, November 22nd. The shares were acquired at an average cost of $10.15 per share, for a total transaction of $2,047,102.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, []

Graphite Bio, Inc. (NASDAQ:GRPH) major shareholder Biocapital L.P. Samsara purchased 201,685 shares of the businesss stock in a transaction that occurred on Monday, November 22nd. The shares were purchased at an average price of $10.15 per share, for a total transaction of $2,047,102.75. The purchase was disclosed in a legal filing with the Securities & []

Virtu Financial LLC acquired a new position in shares of Graphite Bio, Inc. (NASDAQ:GRPH) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 7,709 shares of the companys stock, valued at approximately $237,000. Other hedge funds have also recently added to or reduced their stakes in []